MODULATION OF CYTOKINE RELEASE FROM HUMAN MONOCYTES BY DRUGS USED IN THE THERAPY OF INFLAMMATORY BOWEL DISEASES

被引:0
|
作者
BRUIN, KF [1 ]
HOMMES, DW [1 ]
JANSEN, J [1 ]
TYTGAT, GNJ [1 ]
TENCATE, JW [1 ]
VANDEVENTER, SJH [1 ]
机构
[1] UNIV AMSTERDAM,ACAD MED CTR,CTR HAEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFL,1105 AZ AMSTERDAM,NETHERLANDS
关键词
CYTOKINES; MONOCYTES; INFLAMMATORY BOWEL DISEASE; THERAPY;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Cytokines produced in the gut mucosa play an important role in the pathogenesis of inflammatory bowel diseases (IBD). To determine whether drugs used in the treatment of these diseases modulate cytokine synthesis, we investigated their effects on endotoxin-induced tumour necrosis factor (TNF)-alpha, interleukin (IL)-1 beta and IL-6 release by elutriation-purified human monocytes in vitro. Methods: Drugs tested were dexamethasone, 5-aminosalicylic acid, sulphapyridine and zileuton (a 5-lipoxygenase inhibitor). Monocytes were isolated and stimulated with endotoxin, and TNF, IL-1 and IL-6 levels were determined using an enzyme-linked immunosorbent assay. Results: Monocyte stimulation with endotoxin resulted in an average TNF release of 2464+/-64 pg/10(6) cells, IL-1 release of 616+/-47 pg/10(6) cells and IL-6 release of 2259 +/- 148 pg/10(6) cells. Addition of dexamethasone resulted in a reduction of TNF, IL-1 and IL-6 release to below background levels. Sulphapyridine significantly reduced TNF and induced IL-1 release in a dose-dependent fashion, but had no significant effect on IL-6 release. 5-Aminosalicylic acid did not modulate IL-6 synthesis, but significantly reduced IL-1 and enhanced TNF synthesis. Zileuton reduced TNF and IL-6 release, but enhanced IL-1 release. Conclusion: We conclude that these anti-inflammatory drugs are able to modulate cytokine release by human monocytes. Further studies are needed to determine whether these effects are related to their therapeutic efficacy in IBD.
引用
收藏
页码:791 / 795
页数:5
相关论文
共 50 条
  • [31] Endoscopic Therapy in Inflammatory Bowel Diseases
    Neumann, Helmut
    Neurath, Markus F.
    Atreya, Raja
    VISZERALMEDIZIN, 2015, 31 (04): : 280 - 286
  • [32] Personalizing therapy for inflammatory bowel diseases
    Ananthakrishnan, Ashwin N.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 7 (06) : 549 - 558
  • [33] Therapy for chronic inflammatory Bowel Diseases
    Ots, Thomas
    DEUTSCHE ZEITSCHRIFT FUR AKUPUNKTUR, 2019, 62 (01): : 75 - 76
  • [34] Antioxidant Therapy in Inflammatory Bowel Diseases
    Dziabowska-Grabias, Katarzyna
    Sztanke, Malgorzata
    Zajac, Przemyslaw
    Celejewski, Michal
    Kurek, Katarzyna
    Szkutnicki, Stanislaw
    Korga, Patryk
    Bulikowski, Wlodzimierz
    Sztanke, Krzysztof
    ANTIOXIDANTS, 2021, 10 (03) : 1 - 18
  • [35] The medical Therapy of inflammatory bowel diseases
    Juillerat, Pascal
    THERAPEUTISCHE UMSCHAU, 2018, 75 (05) : 295 - 301
  • [36] MODULATION OF MEDIATOR RELEASE FROM HUMAN INFLAMMATORY CELLS
    MARONE, G
    INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, 1986, 2 (02): : 171 - 179
  • [37] HELICOBACTER-PYLORI STIMULATES CHEMOTACTIC CYTOKINE RELEASE FROM HUMAN MONOCYTES
    BLISS, CM
    KEATES, S
    LINEVSKY, JK
    KELLY, CP
    GASTROENTEROLOGY, 1995, 108 (04) : A785 - A785
  • [38] TNF α MODIFIES THIOREDOXIN-INDUCED CYTOKINE RELEASE FROM HUMAN MONOCYTES
    Leaver, S. K.
    Quinlan, G.
    Evans, T. W.
    Burke-Gaffney, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [39] Inflammatory bowel diseases 2003 -: From genetics to biological therapy
    Schölmerich, J
    DIGESTIVE DISEASES, 2003, 21 (02) : 83 - 84
  • [40] Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy
    Pan, Xiaohua
    Zhu, Qing
    Pan, Li-Long
    Sun, Jia
    PHARMACOLOGY & THERAPEUTICS, 2022, 238